Search results
Showing 1 to 4 of 4 results for siponimod
Siponimod for treating secondary progressive multiple sclerosis (TA656)
Evidence-based recommendations on siponimod (Mayzent) for treating secondary progressive multiple sclerosis in adults.
Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)
Evidence-based recommendations on ponesimod (Ponvory) for treating relapsing–remitting multiple sclerosis in adults.
Cladribine for treating relapsing multiple sclerosis [ID6263]
In development [GID-TA11293] Expected publication date: 23 April 2025
Ofatumumab for treating relapsing multiple sclerosis (TA699)
Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.